Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
Article 2019 en
Authors
TT
Teresa Tsakok
NW
Nina Wilson
ND
Nick Dand
Abstract
1 min read
This real-world study provides evidence that measurement of early serum ustekinumab levels could be useful to direct the treatment strategy for psoriasis. Adequate drug exposure early in the treatment cycle may be particularly important in determining clinical outcome.
Nina Wilkinson, Teresa Tsakok, Nick Dand, Karien Bloem, Michael Duckworth, David Baudry, Angela Pushpa‐Rajah, Christopher Em Griffiths, Nick J. Reynolds, Juliet N. Barker, Richard B. Warren, A. David Burden, Theo Rispens, Deborah Stocken, Catherine Smith
Shan Pan, Teresa Tsakok, Nick Dand, D Lonsdale, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Satveer K. Mahil, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, G Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher Em Griffiths, Nick J. Reynolds, Juliet N. Barker, Richard B. Warren, A. David Burden, Theo Rispens, Joseph F. Standing, Catherine Smith
Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich
K.J. Mason, Juliet N. Barker, Kay Hogan Smith, Philip Hampton, Mark Lunt, Kathleen McElhone, Richard Warren, Zenas Z N Yiu, Christopher Em Griffiths, A. David Burden
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.